• Explore /
  • Poster
  • / Preliminary results of a first-in-human phase I dtudy of IMM01, SIRPα Fc protein in patients with relapsed or refractory lymphoma.

Preliminary results of a first-in-human phase I dtudy of IMM01, SIRPα Fc protein in patients with relapsed or refractory lymphoma.

Abstract Video & Slides Poster

Authors

null

Mingyuan Sun

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College., Tianjin, China

Mingyuan Sun , Junyuan Qi , Weiwei Zheng , Lin Song , Bo Jiang , Zhenzhen Wang , Cheng Huang , Wenzhi Tian , Lugui Qiu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

ChiCTR1900024904

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2550)

DOI

10.1200/JCO.2021.39.15_suppl.2550

Abstract #

2550

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jianliang Yang

First Author: Marouane Maaroufi

First Author: Mark Chang

First Author: Loretta J. Nastoupil